Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio

Integra LifeSciences Holdings Corporation (NASDAQ:IART) recently announced the completed commercial launch of the Integra Titan Reverse Shoulder System-S (RSS-S). This latest offering includes a new glenoid baseplate design to expand the Integra Titan Reverse Shoulder System. The launch is expected to boost the top-line contributions from the Orthopedics and Tissue Technologies segment.

What Makes Titan RSS-S Unique?

Designed with advanced imaging analysis, the new glenoid baseplate enhances fit and provides better stability to patients with various anatomy. Moreover, strong fixation in the patient’s bone is integral for longstanding success of the implant construct in the case of reverse shoulder arthroplasty.

In this regard, RSS-S baseplate is designed to deliver immediate fixation with an independent central screw. Also, glenoid baseplate has a porous-coated central post that enables the patient’s bone to grow onto the implant to further maximize long-term fixation.

Market Potential

Per a report published by Allied Market Research, the global shoulder arthroplasty market is expected to see a CAGR of around 7.6% between 2017 and 2023. Considering the company’s efforts, we believe that it is well-positioned to gain from the favorable trend in the niche space.

Orthopaedics and Tissue Technologies Business

The Orthopedics and Tissue Technologies segment includes specialty metal implants for surgery of the upper and lower extremities, skin and wound repair products and bone grafts as well as nerve and tendon repair products.

The acquisition of Derma Sciences in 2017 provides the company with a relevant scale in outpatient wound care. This has doubled sales in the United States and broadened business base with advanced products such as Medihoney, weight offloading and amniotic tissue. It also creates opportunities to further expand footprint in the plastic and reconstructive surgery segments.

Orthopedics and Tissue Technologies revenues came in at $127 million in the third quarter, up 11.2% year over year. This upside is fueled by a consistent drive in the Regenerative Technologies and Private Label businesses. Notably, the company announced plans within the segment to expand sales channel, improve focus and competitiveness as well as better align product portfolio with clinical customers.

Price Performance

In the past six months, Integra LifeSciences has been consistently underperforming its industry. The stock has declined 28%, in comparison with the 6.6% fall of the industry.

Zacks Rank & Key Picks

Integra LifeSciences carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks in the broader medical space are Veeva Systems (NYSE:VEEV) , Surmodics, Inc (NASDAQ:SRDX) and athenahealth, Inc (NASDAQ:ATHN) .

Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 (Buy).

athenahealth’s long-term earnings growth rate is projected at 17.7%. The stock carries a Zacks Rank of 2.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>